FDA approves Rituxan-corticosteroid combination for Wegener’s Granulomatosis and Microscopic Polyangiitis
FDA approves Rituxan-corticosteroid combination for Wegener’s Granulomatosis and Microscopic Polyangiitis
Genentech, a member of the Roche Group and Biogen Idec announced today that the U.S. Food and Drug Administration (FDA) approved Rituxan® (rituximab), in combination with corticosteroids, as a new medicine for adults with Wegener’s Granulomatosis (WG) and Microscopic Polyangiitis (MPA).
Read more on News-Medical-Net
Categories: Breast Cancer Organizations Tags: approves, combination, Granulomatosis, microscopic, Polyangiitis, Rituxancorticosteroid, Wegener's
AVEO Pharmaceuticals Initiates Patient Enrollment in Phase 1b Tivozanib Combination Trial in Advanced Solid Tumors
AVEO Pharmaceuticals Initiates Patient Enrollment in Phase 1b Tivozanib Combination Trial in Advanced Solid Tumors
AVEO Pharmaceuticals, Inc. , a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has initiated patient enrollment in an open-label, multi-center Phase 1b clinical trial evaluating tivozanib in combination with oral capecitabine in patients with certain advanced solid tumors.
Read more on Business Wire via Yahoo! Finance
Categories: Breast Cancer Tumor Tags: advanced, AVEO, combination, enrollment, Initiates, patient, Pharmaceuticals, Phase, SOLiD, Tivozanib, Trial, Tumors
Merrimack Pharmaceuticals And sanofi-aventis Initiate Enrollment in a Phase 2 Combination Study of MM-121 And …
Merrimack Pharmaceuticals And sanofi-aventis Initiate Enrollment in a Phase 2 Combination Study of MM-121 And …
Merrimack Pharmaceuticals, Inc. and sanofi-aventis announced today that the first patient has received an initial dose in a Phase 2 randomized double blind clinical study combining MM-121 with exemestane (Aromasin®) in breast cancer patients.
Read more on PharmaceuticalOnline
Categories: Metastatic Breast Cancer Tags: combination, enrollment, initiate, Merrimack, MM121, Pharmaceuticals, Phase, SanofiAventis, Study
MMRC initiates Phase Ib/II study of Treanda in combination with Revlimid and dexamethasone
MMRC initiates Phase Ib/II study of Treanda in combination with Revlimid and dexamethasone
The Multiple Myeloma Research Consortium (MMRC) today announced the initiation of a Phase Ib/II study of bendamustine (Treanda®), an anticancer agent currently approved for the treatment of chronic lymphocytic leukemia (CLL) and B-cell non-Hodgkin’s lymphoma (NHL), in combination with lenalidomide (Revlimid®) and dexamethasone in patients with relapsed multiple myeloma. The trial, led by Shaji …
Read more on News-Medical-Net
Categories: Breast Cancer Research Tags: combination, dexamethasone, Ib/II, Initiates, MMRC, Phase, Revlimid, Study, Treanda
Two-drug combination destroys precancerous colon polyps
Two-drug combination destroys precancerous colon polyps
A two-drug combination destroys precancerous colon polyps with no effect on normal tissue, opening a new potential avenue for chemoprevention of colon cancer, a team of scientists at The University of Texas M. D. Anderson Cancer Center reports in the advance online edition of the journal Nature.
Read more on News-Medical-Net
Categories: Breast Cancer Research Tags: colon, combination, destroys, polyps, precancerous, Twodrug